Publications

09/05/2026 04:50:40

Authors: 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND; 2-s2.0-85116918740

Journal: Italy||Italy||Italy||Italy||Italy||Italy

Published: 15470

DOI: University of Padova||University of Padova||University of Padova||University of Padova||University of Padova||University of Padova

Abstract ▼

Volume: Muffato V.; Feraco T.; Miola L.; Tortora C.; Pazzaglia F.; Meneghetti C. Pages: Muffato||Feraco||Miola||Tortora||Pazzaglia||Meneghetti-Finding the shortest path to a destination is a refined navigation ability little explored as yet in familiar environments. The present study examined this ability when walking or describing the path, and how performance relates to individual differences. Sixty-seven undergraduates familiar with the area around their campus were asked to find the shortest path to a destination by walking there or describing it in writing. Several visuospatial tasks and questionnaires were administered. It emerged that shortest path finding performance was supported by familiarity and sense of direction. After accounting for these individual factors, participants performed better when walking than when describing a path. Overall, the results showed that retrieving spatial knowledge about familiar environments relates to individual differences and recall condition, walking a path being easier than describing it.

25/04/2026 04:39:52

Authors: 245 E MAIN ST, ST122, ALHAMBRA, CA 91801 USA; 2-s2.0-85114467298

Journal: Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy

Published: cc-by

DOI: Univer-sita' Cattolica||Fondazione G. Pascale||Fondazione G. Pascale||Azienda Ospedaliera S. Carlo||Università di Padova||Oncologia||Oncologia Medica||Dipartimento di Oncologia Clinica e Sperimentale||Azienda Ospedaliera Treviglio-Caravaggio||AORN A. Cardarelli||IRCCS Fondazione G. Pascale||Azienda Ospedaliera Universitaria Arcispedale Sant' Anna||Ospedale Guglielmo da Saliceto||UOC Medicina Oncologica||Policlinico S. Orsola-Malpighi||Azienda Ospedaliera S. Carlo||Università di Padova||Fondazione G. Pascale||Fondazione G. Pascale||A. O. Ordine Mauriziano||Università della Campania Luigi Vanvitelli||Fondazione G. Pascale||Azienda Ospedaliera G. Rummo

Abstract ▼

Volume: Daniele G.; Schettino C.; Arenare L.; Bilancia D.; Farinati F.; Federico P.; Tamberi S.; Crivellari G.; Barni S.; Tortora R.; Izzo F.; Frassoldati A.; Cavanna L.; Mucciarini C.; Bolondi L.; Dinota A.; Pelizzaro F.; Piccirillo M.C.; Gargiulo P.; Maio M.D.; Gallo C.; Perrone F.; Daniele B. Pages: Daniele||Schettino||Arenare||Bilancia||Farinati||Federico||Tamberi||Crivellari||Barni||Tortora||Izzo||Frassoldati||Cavanna||Mucciarini||Bolondi||Dinota||Pelizzaro||Piccirillo||Gargiulo||Maio||Gallo||Perrone||Daniele-Aim: Only patients with good liver function {[Child-Pugh (CP)] A class} were eligible for trials testing sorafenib as first-line treatment of hepatocellular carcinoma (HCC); nevertheless, the drug was authorized without restrictions based on liver function. Therefore, we planned to test sorafenib efficacy and safety in patients with HCC and deteriorated liver function (CP-B). Methods: This was an open-label, multicenter, randomized phase 3 trial. Patients with HCC, no previous systemic therapy, and CP-B score 7-9 were assigned 1:1 to best supportive care alone (control arm) or with standard dose sorafenib (experimental arm). Overall survival (OS) was the primary endpoint. To detect a 0.70 HR of death, with 80% power, and two-tailed α error 0.05, 234 events were required. The study closed prematurely because of slow accrual. Descriptive analyses are reported. Results: From 2012 to 2017, 13 Italian centers randomized 35 patients. In total, 28 deaths were recorded, 12 without and 16 with sorafenib; median OS was 4.9 (95%CI: 1.2-5.6) and 3.5 months (95%CI: 1.3-5.3), respectively. At least one severe adverse event was reported in 2/15 (13.3%) without and 9/17 (52.9%) patients with sorafenib. Conclusions: This trial failed its planned enrolment goal, showing the difficulty in performing clinical trials with drugs already registered with a label broader than what available evidence supports.

29/04/2026 03:07:13

Authors: ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND; 2-s2.0-85108681688

Journal: Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy

Published: cc-by

DOI: Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore||Azienda Ospedaliero Universitaria Pisana||Azienda Ospedaliero Universitaria Pisana||Azienda Ospedaliero Universitaria Pisana||Università degli Studi di Milano||Università degli Studi di Milano||Padova University Hospital||Padova University Hospital||Padova University Hospital||Università Cattolica del Sacro Cuore||Università Cattolica del Sacro Cuore

Abstract ▼

Volume: Meacci E.; Nachira D.; Zanfrini E.; Evangelista J.; Triumbari E.K.A.; Congedo M.T.; Petracca Ciavarella L.; Chiappetta M.; Vita M.L.; Schinzari G.; Rossi E.; Tortora G.; Lucchi M.; Ambrogi M.; Calabro F.; Petrella F.; Spaggiari L.; Mammana M.; Madrid A.L.; Rea F.; Tabacco D.; Margaritora S. Pages: Meacci||Nachira||Zanfrini||Evangelista||Triumbari||Congedo||Petracca Ciavarella||Chiappetta||Vita||Schinzari||Rossi||Tortora||Lucchi||Ambrogi||Calabrò||Petrella||Spaggiari||Mammana||Madrid||Rea||Tabacco||Margaritora-In this paper we aimed to address the role of pulmonary metastasectomy (PM) in patients affected by Lung Metastases (LM) from Renal Cell Carcinoma (RCC) and to analyse prognostic factors affecting overall survival (OS), disease-free interval (DFI) between primary RCC and first LM, and disease-free survival (DFS) after PM and before lung recurrence. Medical records of 210 patients who underwent PM from RCC in 4 Italian Thoracic Centres, from January 2000 to September 2019, were collected and analysed. All patients underwent RCC resection before lung surgery. The main RCC histology was clear cells (188, 89.5%). The 5-and 10-year OS from the first lung operation were 60% and 34%, respectively. LM synchronous with RCC (p = 0.01) and (Karnofsky Performance Status Scale) KPSS < 80% (p < 0.001) negatively influenced OS. Five-and 10-year DFI were 54% and 28%, respectively. The main factors negatively influencing DFI were: male gender (p = 0.039), KPSS < 80% (p = 0.009) and lactate dehydrogenase > 1.5 times 140 U/L (p = 0.001). Five-and 10-year disease-free survival were 54% and 28%, respectively; multiple LM (p = 0.036), KPSS < 80% (p = 0.001) and histology of RCC other than clear cells negatively influenced disease-free survival. Conclusions: patients with KPSS > 80%, single metachronous LM with a long DFI from RCC diagnosis, and clear cell histology, benefit from pulmonary metastasectomy.

19/04/2026 08:27:21

Authors: MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND; 2-s2.0-85106956473 34072888

Journal: Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy

Published: cc-by

DOI: University of Padua||University of Padua||Roma Tre University of Rome||University of Padua||University of Padua||Roma Tre University of Rome||Roma Tre University of Rome||Roma Tre University of Rome||Roma Tre University of Rome||Roma Tre University of Rome||University of Padua

Abstract ▼

Volume: Brun P.; Zamuner A.; Battocchio C.; Cassari L.; Todesco M.; Graziani V.; Iucci G.; Marsotto M.; Tortora L.; Secchi V.; Dettin M. Pages: Brun||Zamuner||Battocchio||Cassari||Todesco||Graziani||Iucci||Marsotto||Tortora||Secchi||Dettin-Hybrid biomaterials allow for the improvement of the biological properties of materials and have been successfully used for implantology in medical applications. The covalent and selective functionalization of materials with bioactive peptides provides favorable results in tissue engineering by supporting cell attachment to the biomaterial through biochemical cues and interaction with membrane receptors. Since the functionalization with bioactive peptides may alter the chemical and physical properties of the biomaterials, in this study we characterized the biological responses of differently functionalized chitosan analogs. Chitosan analogs were produced through the reaction of GRGDSPK (RGD) or FRHRNRKGY (HVP) sequences, both carrying an aldehyde-terminal group, to chitosan. The bio-functionalized polysaccharides, pure or “diluted” with chitosan, were chemically characterized in depth and evaluated for their antimicrobial activities and biocompatibility toward human primary osteoblast cells. The results obtained indicate that the bio-functionalization of chi-tosan increases human-osteoblast adhesion (p <0.005) and proliferation (p < 0.005) as compared with chitosan. Overall, the 1:1 mixture of HVP functionalized-chitosan:chitosan is the best compromise between preserving the antibacterial properties of the material and supporting osteoblast differentiation and calcium deposition (p < 0.005 vs. RGD). In conclusion, our results reported that a selected concentration of HVP supported the biomimetic potential of functionalized chitosan better than RGD and preserved the antibacterial properties of chitosan.

08/05/2026 06:27:13

Authors: MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND; 2-s2.0-85112011075

Journal: Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy||Italy

Published: cc-by

DOI: University of Naples ‘Federico II’||University of Naples ‘Federico II’||University of Naples ‘Federico II’||University of Naples ‘Federico II’||Sapienza University of Rome||Sapienza University of Rome||University of Campania “Luigi Vanvitelli”||ASST Grande Ospedale Metropolitano Niguarda||University of Pisa||IRCCS San Raffaele Hospital and University||University of Messina||University of Padua||Cardarelli Hospital||Azienda Ospedaliero Universitaria (A.O.U.) di Cagliari||IRCCS Ospedale Policlinico San Martino||Nuovo Ospedale Civile S. Agostino Estense||Azienda Ospedaliero Universitaria (A.O.U.) di Cagliari||University of Naples ‘Federico II’||University of Naples ‘Federico II’||University of Naples ‘Federico II’

Abstract ▼

Volume: Tortora M.; Tranfa M.; D'Elia A.C.; Pontillo G.; Petracca M.; Bozzao A.; Caranci F.; Cervo A.; Cosottini M.; Falini A.; Longo M.; Manara R.; Muto M.; Porcu M.; Roccatagliata L.; Todeschini A.; Saba L.; Brunetti A.; Cocozza S.; Elefante A. Pages: Tortora||Tranfa||D’Elia||Pontillo||Petracca||Bozzao||Caranci||Cervo||Cosottini||Falini||Longo||Manara||Muto||Porcu||Roccatagliata||Todeschini||Saba||Brunetti||Cocozza||Elefante-(1) Although guidelines about the use of MRI sequences for Multiple Sclerosis (MS) diagnosis and follow-up are available, variability in acquisition protocols is not uncommon in everyday clinical practice. The aim of this study was to evaluate the real-world application of MS imaging guidelines in different settings to clarify the level of adherence to these guidelines. (2) Via an on-line anonymous survey, neuroradiologists (NR) were asked about MRI protocols and parameters routinely acquired when MS patients are evaluated in their center, both at diagnosis and followup. Furthermore, data about report content and personal opinions about emerging neuroimaging markers were also retrieved. (3) A total of 46 participants were included, mostly working in a hospital or university hospital (80.4%) and with more than 10 years of experience (47.9%). We found a relatively good adherence to the suggested MRI protocols regarding the use of T2-weighted sequences, although almost 10% of the participants routinely acquired 2D sequences with a slice thickness superior to 3 mm. On the other hand, a wider degree of heterogeneity was found regarding gadolinium administration, almost routinely performed at follow-up examination (87.0% of cases) in contrast with the current guidelines, as well as a low use of a standardized reporting system (17.4% of cases). (4) Although the MS community is getting closer to a standardization of MRI protocols, there is still a relatively wide heterogeneity among NR, with particular reference to contrast administration, which must be overcome to guarantee an adequate quality of patients’ care in MS.

AREA MIN. 02 – Scienze fisiche||AREA MIN. 02 – Scienze fisiche – 15-19 March, 2021

Authors: AREA MIN. 02 - Scienze fisiche

Published: 1778375012223

AREA MIN. 02 – Scienze fisiche||AREA MIN. 02 – Scienze fisiche – 15-19 March, 2021

Authors: AREA MIN. 02 - Scienze fisiche

Published: 1778375013225

AREA MIN. 02 – Scienze fisiche||AREA MIN. 02 – Scienze fisiche – 7th IAA Planetary Defense Conference, held in Vienna, Austria, 26-30 April 2021, id. 196

Authors: AREA MIN. 02 - Scienze fisiche

Published: 1779580867191

12/05/2026 06:04:33

Authors: 1025 VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS; 2-s2.0-85149523343

Journal: United Kingdom||Switzerland||Germany||United Kingdom||France||France||Sweden||New Zealand||United Kingdom||France||Italy||United States||Italy||France||Germany||Spain||Israel||France||United Kingdom||United Kingdom||United States||France||Germany||Italy||Finland||United States||France||Italy||Italy||Italy

Published: cc-by

DOI: University of Leicester||University of Zurich||Max Planck Institute for Solar System Research||Mullard Space Science Laboratory||Institut de Physique du Globe de Paris||Institut de Recherche en Astrophysique et Planétologie||Swedish Institute of Space Physics||University of Canterbury||University of Leicester||Sorbonne Paris Cité||Università degli Studi di Padova||University of Santa-Cruz||Istituto Nazionale di AstroFisica – Istituto di Astrofisica e Planetologia Spaziali (INAF-IAPS)||CNRS||Max Planck Institute for Solar System Research||UPV/EHU||Weizmann Institute of Science||Observatoire de Paris||Imperial College London||University of Leicester||Space Science Institute||Aix Marseille University||University of Rostock||ASI - Italian Space Agency||University of Oulu||NASA Goddard Space Flight Center||Université de Nantes||Università di Bologna||Istituto Nazionale di AstroFisica – Istituto di Astrofisica e Planetologia Spaziali (INAF-IAPS)||Istituto Nazionale di AstroFisica – Istituto di Astrofisica e Planetologia Spaziali (INAF-IAPS)

Abstract ▼

Volume: Fletcher L.N.; Helled R.; Roussos E.; Jones G.; Charnoz S.; Andre N.; Andrews D.; Bannister M.; Bunce E.; Cavalie T.; Ferri F.; Fortney J.; Grassi D.; Griton L.; Hartogh P.; Hueso R.; Kaspi Y.; Lamy L.; Masters A.; Melin H.; Moses J.; Mousis O.; Nettleman N.; Plainaki C.; Schmidt J.; Simon A.; Tobie G.; Tortora P.; Tosi F.; Turrini D. Pages: Fletcher||Helled||Roussos||Jones||Charnoz||André||Andrews||Bannister||Bunce||Cavalié||Ferri||Fortney||Grassi||Griton||Hartogh||Hueso||Kaspi||Lamy||Masters||Melin||Moses||Mousis||Nettleman||Plainaki||Schmidt||Simon||Tobie||Tortora||Tosi||Turrini-Of all the myriad environments in our Solar System, the least explored are the distant Ice Giants Uranus and Neptune, and their diverse satellite and ring systems. These ‘intermediate-sized’ worlds are the last remaining class of Solar System planet to be characterised by a dedicated robotic mission, and may shape the paradigm for the most common outcome of planetary formation throughout our galaxy. In response to the 2019 European Space Agency call for scientific themes in the 2030s and 2040s (known as Voyage 2050), we advocated that an international partnership mission to explore an Ice Giant should be a cornerstone of ESA’s science planning in the coming decade, targeting launch opportunities in the early 2030s. This article summarises the inter-disciplinary science opportunities presented in that White Paper [1], and briefly describes developments since 2019.

02/05/2026 04:24:19

Authors: TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND; 2-s2.0-85139758968

Journal: France||Spain||Spain||France||France||Spain||United Kingdom||Portugal||United Kingdom||France||Switzerland||Belgium||Czech Republic||Italy||France||Japan||Italy||Czech Republic||United Kingdom||Italy||Greece||Germany||Germany||Germany||United States||Switzerland||Italy||United States||United States||United States||United States||United States||United States||United States||United States||Japan||Japan||Japan||Japan||Japan||United States||United States||United States||United States||United States||United States||Netherlands||Netherlands

Published: cc-by

DOI: Laboratoire Lagrange||European Space Astronomy Centre||Universidad de Alicante||Laboratoire Lagrange||CNRS||University of La Laguna||Queen’s University Belfast||Universidade de Lisboa||Open University||Univ. Grenoble Alpes CNRS CNES IPAG||University of Bern||Royal Observatory of Belgium||Czech Academy of Sciences||Department of Physics and Astronomy||Space Systems for Planetary Applications||Institute of Space and Astronautical Science||Istituto di Astrofisica e Planetologia Spaziali-INAF||Astronomical Institute of the Czech Academy of Sciences||Royal Observatory||Department of Industrial Engineering||Aristotle University of Thessaloniki||RB-MUSC||DLR Institute of Planetary Research||Leibniz-Institute for Evolution and Biodiversity Science||University of Maryland||University of Bern||INAF-Osservatorio Astronomico di Roma||JHU/APL||JHU/APL||JHU/APL||JHU/APL||JHU/APL||JHU/APL||University of Maryland||Department of Astronomy and Planetary Science||Department of Planetology||University of Tokyo||Department of Planetology||University of Tokyo||Institute of Space and Astronautical Science||NASA Johnson Space Center||University of Arizona||JHU/APL||Southwest Research Institute||University of Arizona||Southwest Research Institute||ESA/ESTEC||ESA/ESTEC

Abstract ▼

Volume: Michel P.; Kuppers M.; Bagatin A.C.; Carry B.; Charnoz S.; de Leon J.; Fitzsimmons A.; Gordo P.; Green S.F.; Herique A.; Juzi M.; Karatekin O.; Kohout T.; Lazzarin M.; Murdoch N.; Okada T.; Palomba E.; Pravec P.; Snodgrass C.; Tortora P.; Tsiganis K.; Ulamec S.; Vincent J.-B.; Wunnemann K.; Zhang Y.; Raducan S.D.; Dotto E.; Chabot N.; Cheng A.F.; Rivkin A.; Barnouin O.; Ernst C.; Stickle A.; Richardson D.C.; Thomas C.; Arakawa M.; Miyamoto H.; Nakamura A.; Sugita S.; Yoshikawa M.; Abell P.; Asphaug E.; Ballouz R.-L.; Bottke W.F.; Lauretta D.S.; Walsh K.J.; Martino P.; Carnelli I. Pages: Michel||Küppers||Bagatin||Carry||Charnoz||de Leon||Fitzsimmons||Gordo||Green||Hérique||Juzi||Karatekin||Kohout||Lazzarin||Murdoch||Okada||Palomba||Pravec||Snodgrass||Tortora||Tsiganis||Ulamec||Vincent||Wünnemann||Zhang||Raducan||Dotto||Chabot||Cheng||Rivkin||Barnouin||Ernst||Stickle||Richardson||Thomas||Arakawa||Miyamoto||Nakamura||Sugita||Yoshikawa||Abell||Asphaug||Ballouz||Bottke||Lauretta||Walsh||Martino||Carnelli-Hera is a planetary defense mission under development in the Space Safety and Security Program of the European Space Agency for launch in 2024 October. It will rendezvous in late 2026 December with the binary asteroid (65803) Didymos and in particular its moon, Dimorphos, which will be impacted by NASA’s DART spacecraft on 2022 September 26 as the first asteroid deflection test. The main goals of Hera are the detailed characterization of the physical properties of Didymos and Dimorphos and of the crater made by the DART mission, as well as measurement of the momentum transfer efficiency resulting from DART’s impact. The data from the Hera spacecraft and its two CubeSats will also provide significant insights into asteroid science and the evolutionary history of our solar system. Hera will perform the first rendezvous with a binary asteroid and provide new measurements, such as radar sounding of an asteroid interior, which will allow models in planetary science to be tested. Hera will thus provide a crucial element in the global effort to avert future asteroid impacts at the same time as providing world-leading science.